Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market definitions
1.3 Forecast parameters
1.4 Data sources
1.4.1 Secondary
1.4.1.1 Paid sources
1.4.1.2 Unpaid sources
1.4.2 Primary
Chapter 2 Executive Summary
2.1 Onychomycosis treatment industry 360° synopsis, 2016 – 2027
2.1.1 Business trends
2.1.2 Type trends
2.1.3 Treatment type trends
2.1.4 Drug class trends
2.1.5 Distribution channel trends
2.1.6 Regional trends
Chapter 3 Onychomycosis Treatment Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 - 2027
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Increasing prevalence of diabetes worldwide
3.3.1.2 Growing awareness about the potential threats of onychomycosis
3.3.1.3 Rising prevalence of onychomycosis in adults and elderly population
3.3.2 Industry pitfalls and challenges
3.3.2.1 Side effects associated with onychomycosis treatment drugs
3.4 Growth potential analysis
3.4.1 By type
3.4.2 By treatment type
3.4.3 By drug class
3.4.4 By distribution channel
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2020
3.7.1 Competitive matrix analysis, 2020
3.8 PESTEL analysis
Chapter 4 Onychomycosis Treatment Market, By Type
4.1 Key segment trends
4.2 Distal Subungual Onychomycosis (DSO)
4.2.1 Market size, by region, 2016 – 2027
4.3 White Superficial Onychomycosis (WSO)
4.3.1 Market size, by region, 2016 – 2027
4.4 Proximal Subungual Onychomycosis (PSO)
4.4.1 Market size, by region, 2016 – 2027
4.5 Candida Onychomycosis
4.5.1 Market size, by region, 2016 – 2027
4.6 Others
4.6.1 Market size, by region, 2016 – 2027
Chapter 5 Onychomycosis Treatment Market, By Treatment Type
5.1 Key segment trends
5.2 Drug treatment
5.2.1 Market size, by region, 2016 – 2027
5.3 Topical therapy
5.3.1 Market size, by region, 2016 – 2027
Chapter 6 Onychomycosis Treatment Market, By Drug Class
6.1 Key segment trends
6.2 Allylamine
6.2.1 Market size, by region, 2016 – 2027
6.3 Azole
6.3.1 Market size, by region, 2016 – 2027
6.4 Griseofulvin
6.4.1 Market size, by region, 2016 – 2027
6.5 Others
6.5.1 Market size, by region, 2016 – 2027
Chapter 7 Onychomycosis Treatment Market, By Distribution Channel
7.1 Key segment trends
7.2 Hospital Pharmacies
7.2.1 Market size, by region, 2016 – 2027
7.3 Retail Pharmacies
7.3.1 Market size, by region, 2016 – 2027
7.4 Online pharmacies
7.4.1 Market size, by region, 2016 – 2027
Chapter 8 Onychomycosis Treatment Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 Market size, by country 2016 – 2027
8.2.2 Market size, by type, 2016 – 2027
8.2.3 Market size, by treatment type, 2016 – 2027
8.2.4 Market size, by drug class, 2016 – 2027
8.2.5 Market size, by distribution channel, 2016 – 2027
8.2.6 U.S.
8.2.6.1 Market size, by type, 2016 – 2027
8.2.6.2 Market size, by treatment type, 2016 – 2027
8.2.6.3 Market size, by drug class, 2016 – 2027
8.2.6.4 Market size, by distribution channel, 2016 – 2027
8.2.7 Canada
8.2.7.1 Market size, by type, 2016 – 2027
8.2.7.2 Market size, by treatment type, 2016 – 2027
8.2.7.3 Market size, by drug class, 2016 – 2027
8.2.7.4 Market size, by distribution channel, 2016 – 2027
8.3 Europe
8.3.1 Market size, by country 2016 – 2027
8.3.2 Market size, by type, 2016 – 2027
8.3.3 Market size, by treatment type, 2016 – 2027
8.3.4 Market size, by drug class, 2016 – 2027
8.3.5 Market size, by distribution channel, 2016 – 2027
8.3.6 Germany
8.3.6.1 Market size, by type, 2016 – 2027
8.3.6.2 Market size, by treatment type, 2016 – 2027
8.3.6.3 Market size, by drug class, 2016 – 2027
8.3.6.4 Market size, by distribution channel, 2016 – 2027
8.3.7 France
8.3.7.1 Market size, by type, 2016 – 2027
8.3.7.2 Market size, by treatment type, 2016 – 2027
8.3.7.3 Market size, by drug class, 2016 – 2027
8.3.7.4 Market size, by distribution channel, 2016 – 2027
8.3.8 UK
8.3.8.1 Market size, by type, 2016 – 2027
8.3.8.2 Market size, by treatment type, 2016 – 2027
8.3.8.3 Market size, by drug class, 2016 – 2027
8.3.8.4 Market size, by distribution channel, 2016 – 2027
8.3.9 Italy
8.3.9.1 Market size, by type, 2016 – 2027
8.3.9.2 Market size, by treatment type, 2016 – 2027
8.3.9.3 Market size, by drug class, 2016 – 2027
8.3.9.4 Market size, by distribution channel, 2016 – 2027
8.3.10 Spain
8.3.10.1 Market size, by type, 2016 – 2027
8.3.10.2 Market size, by treatment type, 2016 – 2027
8.3.10.3 Market size, by drug class, 2016 – 2027
8.3.10.4 Market size, by distribution channel, 2016 – 2027
8.4 Asia Pacific
8.4.1 Market size, by country 2016 – 2027
8.4.2 Market size, by type, 2016 – 2027
8.4.3 Market size, by treatment type, 2016 – 2027
8.4.4 Market size, by drug class, 2016 – 2027
8.4.5 Market size, by distribution channel, 2016 – 2027
8.4.6 China
8.4.6.1 Market size, by type, 2016 – 2027
8.4.6.2 Market size, by treatment type, 2016 – 2027
8.4.6.3 Market size, by drug class, 2016 – 2027
8.4.6.4 Market size, by distribution channel, 2016 – 2027
8.4.7 Japan
8.4.7.1 Market size, by type, 2016 – 2027
8.4.7.2 Market size, by treatment type, 2016 – 2027
8.4.7.3 Market size, by drug class, 2016 – 2027
8.4.7.4 Market size, by distribution channel, 2016 – 2027
8.4.8 India
8.4.8.1 Market size, by type, 2016 – 2027
8.4.8.2 Market size, by treatment type, 2016 – 2027
8.4.8.3 Market size, by drug class, 2016 – 2027
8.4.8.4 Market size, by distribution channel, 2016 – 2027
8.4.9 South Korea
8.4.9.1 Market size, by type, 2016 – 2027
8.4.9.2 Market size, by treatment type, 2016 – 2027
8.4.9.3 Market size, by drug class, 2016 – 2027
8.4.9.4 Market size, by distribution channel, 2016 – 2027
8.4.10 Australia
8.4.10.1 Market size, by type, 2016 – 2027
8.4.10.2 Market size, by treatment type, 2016 – 2027
8.4.10.3 Market size, by drug class, 2016 – 2027
8.4.10.4 Market size, by distribution channel, 2016 – 2027
8.5 Latin America
8.5.1 Market size, by country 2016 – 2027
8.5.2 Market size, by type, 2016 – 2027
8.5.3 Market size, by treatment type, 2016 – 2027
8.5.4 Market size, by drug class, 2016 – 2027
8.5.5 Market size, by distribution channel, 2016 – 2027
8.5.6 Brazil
8.5.6.1 Market size, by type, 2016 – 2027
8.5.6.2 Market size, by treatment type, 2016 – 2027
8.5.6.3 Market size, by drug class, 2016 – 2027
8.5.6.4 Market size, by distribution channel, 2016 – 2027
8.5.7 Mexico
8.5.7.1 Market size, by type, 2016 – 2027
8.5.7.2 Market size, by treatment type, 2016 – 2027
8.5.7.3 Market size, by drug class, 2016 – 2027
8.5.7.4 Market size, by distribution channel, 2016 – 2027
8.5.8 Argentina
8.5.8.1 Market size, by type, 2016 – 2027
8.5.8.2 Market size, by treatment type, 2016 – 2027
8.5.8.3 Market size, by drug class, 2016 – 2027
8.5.8.4 Market size, by distribution channel, 2016 – 2027
8.6 Middle East and Africa
8.6.1 Market size, by country 2016 – 2027
8.6.2 Market size, by type, 2016 – 2027
8.6.3 Market size, by treatment type, 2016 – 2027
8.6.4 Market size, by drug class, 2016 – 2027
8.6.5 Market size, by distribution channel, 2016 – 2027
8.6.6 Saudi Arabia
8.6.6.1 Market size, by type, 2016 – 2027
8.6.6.2 Market size, by treatment type, 2016 – 2027
8.6.6.3 Market size, by drug class, 2016 – 2027
8.6.6.4 Market size, by distribution channel, 2016 – 2027
8.6.7 UAE
8.6.7.1 Market size, by type, 2016 – 2027
8.6.7.2 Market size, by treatment type, 2016 – 2027
8.6.7.3 Market size, by drug class, 2016 – 2027
8.6.7.4 Market size, by distribution channel, 2016 – 2027
8.6.8 South Africa
8.6.8.1 Market size, by type, 2016 – 2027
8.6.8.2 Market size, by treatment type, 2016 – 2027
8.6.8.3 Market size, by drug class, 2016 – 2027
8.6.8.4 Market size, by distribution channel, 2016 – 2027
Chapter 9 Company Profiles
9.1 Strategy dashboard, 2020
9.2 Novartis AG
9.2.1 Business overview
9.2.2 Financial data
9.2.3 Product landscape
9.2.4 Strategic outlook
9.2.5 SWOT analysis
9.3 Pfizer Inc.
9.3.1 Business overview
9.3.2 Financial data
9.3.3 Product landscape
9.3.4 Strategic outlook
9.3.5 SWOT analysis
9.4 Galderma Laboratories
9.4.1 Business overview
9.4.2 Financial data
9.4.3 Product landscape
9.4.4 Strategic outlook
9.4.5 SWOT analysis
9.5 Bausch Health Sciences
9.5.1 Business overview
9.5.2 Financial data
9.5.3 Product landscape
9.5.4 Strategic outlook
9.5.5 SWOT analysis
9.6 Moberg Pharma AB
9.6.1 Business overview
9.6.2 Financial data
9.6.3 Product landscape
9.6.4 Strategic outlook
9.6.5 SWOT analysis
9.7 Dr. Reddy’s Laboratories Ltd
9.7.1 Business overview
9.7.2 Financial data
9.7.3 Product landscape
9.7.4 Strategic outlook
9.7.5 SWOT analysis
9.8 Medimetriks Pharmaceuticals Inc.
9.8.1 Business overview
9.8.2 Financial data
9.8.3 Product landscape
9.8.4 Strategic outlook
9.8.5 SWOT analysis
9.9 Merz Pharma
9.9.1 Business overview
9.9.2 Financial data
9.9.3 Product landscape
9.9.4 Strategic outlook
9.9.5 SWOT analysis
9.10 Kaken Pharmaceutical Co. Ltd
9.10.1 Business overview
9.10.2 Financial data
9.10.3 Product landscape
9.10.4 Strategic outlook
9.10.5 SWOT analysis
9.11 Johnson & Johnson Services Inc.
9.11.1 Business overview
9.11.2 Financial data
9.11.3 Product landscape
9.11.4 Strategic outlook
9.11.5 SWOT analysis
9.12 GlaxoSmithKline plc
9.12.1 Business overview
9.12.2 Financial data
9.12.3 Product landscape
9.12.4 Strategic outlook
9.12.5 SWOT analysis
9.13 Taro Pharmaceuticals Industries Ltd
9.13.1 Business overview
9.13.2 Financial data
9.13.3 Product landscape
9.13.4 Strategic outlook
9.13.5 SWOT analysis
